14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
INKT vs AETH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
AETH Captures Overall Composite Edge (56.5 HOLD vs 42.8 HOLD), While INKT Leads 3–1 on Growth & Valuation Pillars
AETH Overall Winner
6-Pillar Tally: INKT 3 – 1 AETH (2 Tie)
Matrix Metrics: INKT 5 – 3 AETH
As of Nov 20, 2026, Bitwise Trendwise Ether and Treasuries Rotation Strategy ETF (AETH) captures the overall head-to-head institutional edge over MiNK Therapeutics, Inc. (INKT) on higher Unified Composite conviction (56.5/100 HOLD vs. 42.8/100 HOLD) after splitting the core matrix 3–5 (led by Options & Positioning), while INKT wins 3–1 across the 6-pillar growth and valuation breakdown. INKT trades at $8.02 (N/M Forward P/E, -5720.7% operating margin) versus AETH at $37.54 (N/M Forward P/E, N/A operating margin).
Growth vs. Quality Trade-Off: AETH earns the overall head-to-head edge with a stronger Unified Composite Score (56.5/100 HOLD vs. INKT 42.8/100 HOLD) and 0.96β · 29% Vol risk profile, whereas INKT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: INKT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile AETH trades in a Markup technical trend (SURGE options phase, RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INKT vs AETH. Trailing 12-month operating profitability (INKT -5720.7% vs AETH N/A) and valuation multiples (INKT N/M vs AETH N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $44.2M market capitalization and -5720.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
AETH Moat ProfileCyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ INKT vs AETH Key Questions & Quantitative Answers
As of Nov 20, 2026, Bitwise Trendwise Ether and Treasuries Rotation Strategy ETF (AETH) captures the overall head-to-head institutional edge over MiNK Therapeutics, Inc. (INKT) on higher Unified Composite conviction (56.5/100 HOLD vs. 42.8/100 HOLD) after splitting the core matrix 3–5 (led by Options & Positioning), while INKT wins 3–1 across the 6-pillar growth and valuation breakdown. INKT trades at $8.02 (N/M Forward P/E, -5720.7% operating margin) versus AETH at $37.54 (N/M Forward P/E, N/A operating margin). Growth vs. Quality Trade-Off: AETH earns the overall head-to-head edge with a stronger Unified Composite Score (56.5/100 HOLD vs. INKT 42.8/100 HOLD) and 0.96β · 29% Vol risk profile, whereas INKT leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: INKT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile AETH trades in a Markup technical trend (SURGE options phase, RSI 54.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
INKT leads the Growth & Scale pillar: INKT posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $200,000 TTM revenue (100.0% gross margin, -5720.7% operating margin), compared with AETH at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, INKT generates $200,000 in USD-normalized revenue versus N/A for AETH. In operating R&D and SG&A reinvestment, INKT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AETH.
INKT and AETH trade at balanced relative valuation multiples. INKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AETH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INKT (-1239.0% ROE) versus AETH (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, INKT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 55% Vol realized risk). By comparison, AETH carries 9.5% implied volatility (1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.96β · 29% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.